In short
- Revenue decreased from ¥60 million in the same period of the previous year to ¥52 million.
- The net loss widened by ¥20 million year on year to ¥399 million.
- The company entered into a joint research agreement with KYORIN Pharmaceutical Co.,Ltd. to pursue the creation of novel antibody medicines.
What they reported
this period against the same period a year earlier, and where they now expect the year to endSales
| Period | ¥m |
|---|---|
| FY25 Q1 | 20.0 |
| FY25 Q2 | 39.0 |
| FY25 Q3 | 24.0 |
| FY25 Q4 | 37.0 |
| FY26 Q1 | 23.0 |
| FY26 Q2 | 37.0 |
| FY26 Q3 | 43.0 |
| FY26 Q4 | 32.0 |
| FY27 Q1 | 35.0 |
| FY27 Q2 | 17.0 |
Revenue decreased year on year.
売上高:前年同期比約13.7%減Operating profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -221.0 |
| FY25 Q2 | -193.0 |
| FY25 Q3 | -216.0 |
| FY25 Q4 | -196.0 |
| FY26 Q1 | -218.0 |
| FY26 Q2 | -181.0 |
| FY26 Q3 | -174.0 |
| FY26 Q4 | -171.0 |
| FY27 Q1 | -204.0 |
| FY27 Q2 | -207.0 |
Ordinary profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -214.0 |
| FY25 Q2 | -213.0 |
| FY25 Q3 | -197.0 |
| FY25 Q4 | -205.0 |
| FY26 Q1 | -171.0 |
| FY26 Q2 | -174.0 |
| FY26 Q3 | -164.0 |
| FY26 Q4 | -169.0 |
| FY27 Q1 | -201.0 |
| FY27 Q2 | -193.0 |
Net profit
| Period | ¥m |
|---|---|
| FY25 Q1 | -219.0 |
| FY25 Q2 | -276.0 |
| FY25 Q3 | -199.0 |
| FY25 Q4 | -210.0 |
| FY26 Q1 | -176.0 |
| FY26 Q2 | -203.0 |
| FY26 Q3 | -168.0 |
| FY26 Q4 | -171.0 |
| FY27 Q1 | -202.0 |
| FY27 Q2 | -197.0 |
The net loss widened due to lower revenue and a decrease in subsidies.
純利益:売上減影響及び助成金減により前年同期比20百万円損失増Their own numbers
figures this company chose to report, a year ago against nowA physician-initiated clinical trial of PPMX-T003 is being conducted at 10 medical institutions nationwide.
The low–high ranges are Komori's estimate, not figures the company gave.
Everything else in the deck
New initiatives
- The company entered into a joint research agreement with KYORIN Pharmaceutical Co.,Ltd. to pursue the creation of novel antibody medicines.
- The company advanced its joint research with Eurus Therapeutics Co., Ltd. and entered into a new agreement.
What decks usually leave out
COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deckMargins and overheads
Overheads (selling and admin costs): ¥458.0m
Financial targets
| Period | % |
|---|---|
| FY23 | -28.3 |
| FY24 | -58.2 |
| FY25 | -63.9 |
| FY26 | -54.2 |
| Period | % |
|---|---|
| FY22 | 95.5 |
| FY23 | 92.1 |
| FY24 | 78.2 |
| FY25 | 74.4 |
| FY26 | 70.1 |
| FY27 | 62.7 |
Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.